ASX:NEUPharmaceuticals
How Investors May Respond To Neuren Pharmaceuticals (ASX:NEU) 2025 Results, Buy-Back Plan And Pipeline Progress
Neuren Pharmaceuticals recently reported its full-year 2025 results, with revenue of A$84.84 million and net income of A$30.44 million, alongside a trading pause on the ASX pending a market-sensitive announcement.
Despite lower year-on-year earnings, Neuren highlighted increased DAYBUE royalties, a new share buy-back program, and progress in its NNZ-2591 pipeline, including an FDA Fast Track designation, underscoring the company’s focus on advancing its rare neurological disorder...